Document resource
MINORE ( NCT04998812) is a prospective Phase IV, open-label study measuring ocrelizumab placental transfer, infant B-cell levels and detailed maternal and infant clinical outcomes, humoral immunity and safety.Thirty-five women were enrolled, 32 of whom received ocrelizumab within 6 months before last menstrual period (LMP) (3–6 months before LMP, n=18; and 0–3 months before LMP, n=14), and three women received ocrelizumab in the first trimester.The primary endpoint was the proportion of infants with B-cell levels below the lower limit of normal (LLN), measured at week 6 (W6) of life.All 35 pregnancies resulted in full-term live births. Ocrelizumab was undetectable in most infants, both in the umbilical cord blood at birth (94.3%, 33/35) and serum at W6 of life (97.0%, 32/33). All infant B-cell levels were above the age-specific LLN at W6 (100%, 34/34). Rates and types of adverse events (AEs) in mothers were in line with expected AEs during pregnancy, delivery, postpartum and infancy.Results of this study indicate that pregnancy planning is compatible with ocrelizumab treatment and support treatment decisions by clinicians and women with MS.ruth.dobson@qmul.ac.uk